AACR Cancer Progress Report Highlights How Discovery Science is Driving Clinical Breakthroughs
Fifty years after the signing of the National Cancer Act, rapid progress against cancer for patients continues Medical research...
Fifty years after the signing of the National Cancer Act, rapid progress against cancer for patients continues Medical research...
PHILADELPHIA — The American Association for Cancer Research (AACR) today expressed its gratitude to Francis S. Collins, MD, PhD,...
PHILADELPHIA – A peptide-drug conjugate that targets the acidic environment of cancer cells enhanced the efficacy of immune checkpoint...
PHILADELPHIA – In preclinical models, combining an investigational Aurora Kinase A (AURKA) inhibitor with a KRAS inhibitor or a...
PHILADELPHIA – Combination of the KRAS inhibitor sotorasib (Lumakras) with afatinib, a pan-ErbB tyrosine kinaseinhibitor, was feasible in treating...
PHILADELPHIA – In a phase II clinical trial, the drug 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) improved survival for some adolescent and young...
PHILADELPHIA – Black/African American patients with prostate cancer who were treated with the androgen receptor inhibitor darolutamide (Nubeqa) had...
Modifying criteria could help researchers enroll more Black patients in trials PHILADELPHIA – A simulated pancreatic cancer clinical trial...
PHILADELPHIA – Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival...
Data could help identify factors that contribute to higher risk PHILADELPHIA – Chinese Americans and Laotian Americans were over...